Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Multiple flow rate modelling of nitric oxide in COPD – methodological concerns

Kay Roy, Zoe Borrill, Andrew Hazel, Jorgen Vestbo, Dave Singh
European Respiratory Review 2006 15: 213-214; DOI: 10.1183/09059180.00010129
Kay Roy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoe Borrill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Hazel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorgen Vestbo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dave Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Multiple flow rates FeNO data two-compartment mathematical modelling can estimate NO airway wall concentration (CawNO), airway wall diffusing capacity (DawNO), alveolar concentration (CalvNO) and maximal NO flux (JawNO). To compare modelling based on linear, non linear and mixed linear and non linear analyses in COPD. FeNO was measured using the Niox analyser (Aerocrine) at flow rates: 10, 30, 50, 100 and 200ml/s in 50 COPD patients and the data applied to 4 different methods. All methods showed that current smoking reduced CawNO. JawNO data differed between methods (Table 1⇓). All the methods showed that current smoking did not affect CalvNO or DawNO. Comparison of the methods showed that CalvNO and DawNO data were significantly different between all methods, JawNO was different for most between method comparisons, while there was agreement between all the methods for CawNO. Smoking in COPD reduces CawNO , but not CalvNO and DawNO. JawNO, CalvNO and DawNO data are model dependent parameters. CawNO findings were model independent, and hence the most robust modelled parameter.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

MY JOB AND THE UNIT IN WHICH I WORK

I am currently pursuing a PhD investigating the role of endogenous nitric oxide (NO) in chronic obstructive pulmonary disease (COPD) airway inflammation. By the end of this article, I hope that the importance of this topic will be highlighted and insight provided into the COPD research team which I am a part of in the North West Lung Centre (NWLC), Manchester, UK.

MY WINNING POSTER AS PART OF MY RESEARCH

In light of our increased awareness of the heterogeneity of inflammatory respiratory diseases, such as asthma and COPD, it is now recognised that different clinical phenotypes of the disease may have different treatment responses. The field of noninvasive biomarkers has developed rapidly over the last few years in the search of easy and effective means of measuring and monitoring inflammatory status, thus allowing the response to treatment to be assessed. This is where NO comes into the story.

Despite the immense amount of work evaluating the role of exhaled nitric oxide fraction (Fe,NO) as a marker of disease control in asthma, there have been markedly fewer studies in COPD. The main reason for not persevering in this disease group could be that initial studies showed that current smoking decreased airway NO levels, and so the results were not as exciting as those in asthmatics. However, looking closely at published data, we thought that there was still a population of COPD patients in whom Fe,NO levels were raised.

The response to corticosteroids in COPD is often poor. This condition is one of the biggest burdens on the health services worldwide, making the need to improve current treatment strategies of great importance. The phenotypic characterisation of COPD would be of value in defining distinct clinical subgroups that may respond differently to interventions.

At the NWLC, I am involved in the phenotypic characterisation of a large cohort of COPD patients, in whom I have also measured Fe,NO and NO metabolites in exhaled breath condensate and sputum supernatant. The aim is to identify a subset with raised levels of NO and to understand the pathophysiological characteristics of these patients.

The data that was presented at the 2006 European Respiratory Society Congress in Munich was obtained from multiple flow rates of Fe,NO applied to a mathematical model in order to estimate concentrations of NO in the alveolar and bronchial walls of the airways. The location of inflammation in the bronchial tree may influence reponse to treatment; asthmatics with more refractory disease have been found to have higher alveolar concentrations of NO. As with any new technique, a number of methodological issues must be resolved on the path to developing a standardised approach; this is a key area that we have always tackled in our team and that I have addressed in this award-winning abstract which looks at NO modelling. The study was provoked by the fact that there was no gold standard method for the modelling of NO in the airways, yet important conclusions about the anatomical distribution of NO were being drawn by published papers. Our study shows that different modelling methods give rise to different results, underscoring the need to standardise NO multiple flow rate modelling. We were also able to show that smoking reduced airway wall concentration of NO and it was this parameter that proved to be the most robust.

Focusing on the molecular aspects, I now aim to investigate the contribution of NO at a cellular level in airway cells. I will study its effects on glucocorticoid pharmacology. With access to cells from lung tissue resection and bronchoscopy specimens, we have ample opportunity to expose cells to NO and explore changes in mediator release, gene expression and, importantly, protein modification. This may answer questions about the roles of modified proteins in disease progression and about drug effects. I hope that my work will initiate sufficient discussion to prompt further research studying the role of NO in COPD.

MY RESEARCH AS PART OF MY WORKING GROUP/RESEARCH TEAM

I am only a small part of a much bigger organisation here at NWLC, which houses researchers across the fields of COPD and asthma. Phase 2 and 3 clinical trials are conducted at a new 18-bed unit, the Medicines Evaluation Unit (MEU), which is fully equipped for full pulmonary physiology testing (including plethysmography and impulse oscillometry) and has on-site laboratory and bronchoscopy facilities. Our new state-of-the-art refurbished laboratory is fully set up for tissue culture, immunohistochemisty, flow cytometry, Western blotting and real-time PCR. There are studies of both adaptive and innate immune function currently ongoing in this laboratory.

THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE

In terms of clinical phenotypic research, as well as the establishment of the COPD cohort mentioned previously, we have developed a sister cohort for asthmatic smokers, again for epidemiological studies and longitudinal follow-up. A key area of interest is the study of biomarkers in sputum and exhaled breath, and their application in clinical trials.

Team members include three postdoctoral scientists and seven PhD students with support from various clinical and laboratory-based technicians. The COPD team is led by Dr Dave Singh (Senior Lecturer in Clinical Pharmacology and Consultant Respiratory Physician) and Prof. Jorgen Vestbo. Dave Singh's expertise in the design and running of clinical trials combined with its interface with molecular science greatly compliments the internationally recognised work of Jorgen Vestbo in the epidemiology of COPD. Both individuals provide excellent supervision and support for the clinical and laboratory researchers, allowing an extensive level of COPD research to occur from the laboratory to the ward.

View this table:
  • View inline
  • View popup
    • © ERSJ Ltd
    PreviousNext
    Back to top
    View this article with LENS
    Vol 15 Issue 101 Table of Contents
    European Respiratory Review: 15 (101)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Multiple flow rate modelling of nitric oxide in COPD – methodological concerns
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Multiple flow rate modelling of nitric oxide in COPD – methodological concerns
    Kay Roy, Zoe Borrill, Andrew Hazel, Jorgen Vestbo, Dave Singh
    European Respiratory Review Dec 2006, 15 (101) 213-214; DOI: 10.1183/09059180.00010129

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Multiple flow rate modelling of nitric oxide in COPD – methodological concerns
    Kay Roy, Zoe Borrill, Andrew Hazel, Jorgen Vestbo, Dave Singh
    European Respiratory Review Dec 2006, 15 (101) 213-214; DOI: 10.1183/09059180.00010129
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • MY JOB AND THE UNIT IN WHICH I WORK
      • MY WINNING POSTER AS PART OF MY RESEARCH
      • MY RESEARCH AS PART OF MY WORKING GROUP/RESEARCH TEAM
      • THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Clinical and public health significance of treatments to aid smoking cessation
    • Implications and priorities of tobacco control in Belgium and Europe
    • The psychobiology of nicotine dependence
    Show more Original Articles

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERR

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising
    • Sponsorship

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 0905-9180
    Online ISSN: 1600-0617

    Copyright © 2022 by the European Respiratory Society